Skip to main content
. 2017 Feb 13;11(2):189–195. doi: 10.5009/gnl15562

Fig. 4.

Fig. 4

Virologic response (hepatitis B virus [HBV] DNA <60 IU/mL) by tenofovir disoproxil fumarate (TDF) monotherapy versus TDF and entecavir (ETV) combination therapy in ETV-resistant patients with chronic hepatitis B in a randomized controlled trial. Intention-to-treat population shown. Adapted from Lim YS, et al. Gut 2016;65:852–860.31